Cargando…
Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis?
Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953000/ https://www.ncbi.nlm.nih.gov/pubmed/31817891 http://dx.doi.org/10.3390/cells8121591 |
_version_ | 1783486550113255424 |
---|---|
author | Reiche, Laura Küry, Patrick Göttle, Peter |
author_facet | Reiche, Laura Küry, Patrick Göttle, Peter |
author_sort | Reiche, Laura |
collection | PubMed |
description | Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and astrogliosis. Recent studies mainly focused on neuronal development in DS, but underestimated the role of glial cells as pathogenic players. Aberrant or impaired differentiation within the oligodendroglial lineage and altered white matter functionality are thought to contribute to central nervous system (CNS) malformations. Given that white matter, comprised of oligodendrocytes and their myelin sheaths, is vital for higher brain function, gathering knowledge about pathways and modulators challenging oligodendrogenesis and cell lineages within DS is essential. This review article discusses to what degree DS-related effects on oligodendroglial cells have been described and presents collected evidence regarding induced cell-fate switches, thereby resulting in an enhanced generation of astrocytes. Moreover, alterations in white matter formation observed in mouse and human post-mortem brains are described. Finally, the rationale for a better understanding of pathways and modulators responsible for the glial cell imbalance as a possible source for future therapeutic interventions is given based on current experience on pro-oligodendroglial treatment approaches developed for demyelinating diseases, such as multiple sclerosis. |
format | Online Article Text |
id | pubmed-6953000 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-69530002020-01-23 Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? Reiche, Laura Küry, Patrick Göttle, Peter Cells Review Down syndrome (DS), or trisomy 21, is the most prevalent chromosomal anomaly accounting for cognitive impairment and intellectual disability (ID). Neuropathological changes of DS brains are characterized by a reduction in the number of neurons and oligodendrocytes, accompanied by hypomyelination and astrogliosis. Recent studies mainly focused on neuronal development in DS, but underestimated the role of glial cells as pathogenic players. Aberrant or impaired differentiation within the oligodendroglial lineage and altered white matter functionality are thought to contribute to central nervous system (CNS) malformations. Given that white matter, comprised of oligodendrocytes and their myelin sheaths, is vital for higher brain function, gathering knowledge about pathways and modulators challenging oligodendrogenesis and cell lineages within DS is essential. This review article discusses to what degree DS-related effects on oligodendroglial cells have been described and presents collected evidence regarding induced cell-fate switches, thereby resulting in an enhanced generation of astrocytes. Moreover, alterations in white matter formation observed in mouse and human post-mortem brains are described. Finally, the rationale for a better understanding of pathways and modulators responsible for the glial cell imbalance as a possible source for future therapeutic interventions is given based on current experience on pro-oligodendroglial treatment approaches developed for demyelinating diseases, such as multiple sclerosis. MDPI 2019-12-07 /pmc/articles/PMC6953000/ /pubmed/31817891 http://dx.doi.org/10.3390/cells8121591 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Reiche, Laura Küry, Patrick Göttle, Peter Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title | Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title_full | Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title_fullStr | Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title_full_unstemmed | Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title_short | Aberrant Oligodendrogenesis in Down Syndrome: Shift in Gliogenesis? |
title_sort | aberrant oligodendrogenesis in down syndrome: shift in gliogenesis? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953000/ https://www.ncbi.nlm.nih.gov/pubmed/31817891 http://dx.doi.org/10.3390/cells8121591 |
work_keys_str_mv | AT reichelaura aberrantoligodendrogenesisindownsyndromeshiftingliogenesis AT kurypatrick aberrantoligodendrogenesisindownsyndromeshiftingliogenesis AT gottlepeter aberrantoligodendrogenesisindownsyndromeshiftingliogenesis |